Chronic kidney disease

53 (suppl 3): S107–14.
141 Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. 
Screening for proteinuria in US adults: a cost-eff ectiveness analysis. 
JAMA 2003; 290: 3101–14.
142 Hoerger TJ, Wittenborn JS, Segel JE, et al, for the Centers for 
Disease Control and Prevention CKD Initiative. A health policy 
model of CKD: 2. The cost-eff ectiveness of microalbuminuria 
screening. Am J Kidney Dis 2010; 55: 463–73.
143 Manns B, Hemmelgarn B, Tonelli M, et al, for the Alberta Kidney 
Disease Network. Population based screening for chronic kidney 
disease: cost eff ectiveness study. BMJ 2010; 341: c5869.
144 Asselbergs FW, Diercks GF, Hillege HL, et al, for the Prevention 
of Renal and Vascular Endstage Disease Intervention Trial 
(PREVEND IT) Investigators. Eff ects of fosinopril and pravastatin 
on cardiovascular events in subjects with microalbuminuria. 
Circulation 2004; 110: 2809–16.

---

Document Outline

• Chronic kidney disease
  • Introduction
  • Conceptual model, definitions, and outcomes
  • Causes
  • Prevalence
  • Detection and assessment
  • Management
    • Concepts
    • Slowing progression of chronic kidney disease and reduction of albuminuria
    • Prevention of complications from decreased GFR
      • Threats to patient safety
      • Uraemic complications
    • Treatment of nephrotic syndrome
    • Dialysis and transplantation
    • Reductions in risk of cardiovascular disease
  • Controversies and challenges
    • Association with ageing and vascular disease
    • Clinical trials
    • Guidelines
    • Chronic kidney disease as a public health problem
  • Acknowledgments
  • References